Journal
ACADEMIC EMERGENCY MEDICINE
Volume 22, Issue 1, Pages 94-112Publisher
WILEY
DOI: 10.1111/acem.12538
Keywords
-
Categories
Funding
- NIH/NHLBI [K12HL1090]
- Medtronic
- Cardiorentis
- Abbott Point-of-Care
- Novartis
- Medicines Company
- Astellas
- Intersection Medical
- Radiometer
- Abbott Diagnostics
- Centers for Medicaid and Medicare Services (CMS)
- National Center for Advancing Translational Sciences [UL1TR000445]
- Roche Diagnostics
- National Institutes of Health
- European Union
- Health Resources Service Administration
- NIH
- Amgen
- Trevena
- Portola
- Siemens
- Mayday Foundation
- Pfizer
- NHLBI
- Sanofi Aventis
- Dyax
- Insys
- Novartis Pharmaceuticals
- Cardiorentis Inc.
- Trevena Inc.
- Mespere
- BG Medicine
- NIH/NIMHD [5 R01 MD005849-04]
- Alere
- Abbott
- Acorda Therapeutics Inc.
- Cardio3 Bioscience
- Cytokinetics
- Sorbent Therapeutics
- St. Jude
Ask authors/readers for more resources
Heart failure (HF) afflicts nearly 6 million Americans, resulting in 1million emergency department (ED) visits and over 1million annual hospital discharges. The majority of inpatient admissions originate in the ED; thus, it is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics, and alternatives to hospitalization. This article discusses contemporary ED management as well as the necessary next steps for ED-based acute HF research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
